Anti-beta2GPI antibody or antigen binding fragment thereof as well as preparation method and application thereof
By preparing anti-β2GPI antibodies or their antigen-binding fragments with specific amino acid sequences and framework regions, the problems of antibody stability and safety in existing technologies have been solved, enabling precise recognition and killing of CAAR-T cells and improving the immunotherapy efficacy for β2GPI-related diseases.
Patent Information
- Application Number
- CN202610231073.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-02-26
- Publication Date
- 2026-07-17
AI Technical Summary
There is a lack of stable and reproducible functional anti-β2GPI antibodies in the current technology to verify the effectiveness of CAAR-T cell recognition, activation and killing. Furthermore, full-length IgG antibodies may cause coagulation interference, affecting safe application and making it difficult to achieve precise immunotherapy for β2GPI-related diseases.
Provide anti-β2GPI antibodies or their antigen-binding fragments, including specific amino acid sequences and framework regions, and CDRs defined by the Kabat, Chothia, IMGT, Contact, or AbM numbering systems for the preparation of murine, humanized, or fully human antibodies that bind to β2GPI domain 1 for the construction and evaluation of CAAR-T cells.
It provides stable and reproducible anti-β2GPI antibodies for precise recognition and killing of CAAR-T cells, reduces the risk of coagulation interference, and improves the safety and efficacy of immunotherapy for β2GPI-related diseases.